Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma
Rasco, D Middleton, M Gonzalez, Rene Corrie, P Pavlick, A Lorigan, Paul C Plummer, R Gore, M Herbert, C Agarwala, S
Rasco, D
Middleton, M
Gonzalez, Rene
Corrie, P
Pavlick, A
Lorigan, Paul C
Plummer, R
Gore, M
Herbert, C
Agarwala, S
Citations
Altmetric:
Abstract
Description
Date
2015
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. 2015, 51 S53-S54 Eur J Cancer